{"abstract": "Bristol-Myers Squibb has inspired all kinds of takeover speculation recently. There has been less talk about Wyeth, an even larger pharmaceuticals giant that Catherine Arnold, an analyst at Credit Suisse, thinks could be an acquisition target as well. In a report Monday on possible mergers and acquisitions activity in the drug industry, Ms. Arnold also identified two drugmakers that appear to be \u201cnatural acquirers\u201d: GlaxoSmithKline and Novartis. ", "web_url": "https://dealbook.nytimes.com/2007/03/19/diagnosing-the-next-big-drug-deal/", "snippet": "", "lead_paragraph": "Bristol-Myers Squibb has inspired all kinds of takeover speculation recently. There has been less talk about Wyeth, an even larger pharmaceuticals giant that Catherine Arnold, an analyst at Credit Suisse, thinks could be an acquisition target as well. In a report Monday on possible mergers and acquisitions activity in the drug industry, Ms. Arnold also identified two drugmakers that appear to be \u201cnatural acquirers\u201d: GlaxoSmithKline and Novartis. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Diagnosing the Next Big Drug Deal", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2007-03-19T18:08:04+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By", "person": [], "organization": null}, "type_of_material": "News", "_id": "nyt://article/f6f2da75-653f-5059-b906-2da2fc9e4f99", "word_count": 294, "uri": "nyt://article/f6f2da75-653f-5059-b906-2da2fc9e4f99"}